Oral cancer is the sixth most common type of cancer worldwide, especially oral squamous cell carcinoma. Most intraoral tumors are treated by a combination of surgery and radiotherapy. For those cases where progression is still observed after the conventional treatment options, other newer options became available, such as immune checkpoint inhibitors. Those drugs have shown great success as a treatment approach for head and neck cancer, and after highly positive outcome in clinical trials, both nivolumab and pembrolizumab, PD-1 blockers, were approved by the FDA as a treatment for head and neck cancer.